The role of complement in membranous nephropathy

Seminars in Nephrology

Volumn 33, Issue 6, 2013, Pages 531-542

  Ma, Hong ^a   Sandor, Dana G ^a   Beck, Laurence H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Complement; IgG4; Membranous nephropathy; Phospholipase A2 receptor; PLA2R

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; IMMUNOGLOBULIN G4; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ARTICLE; AUTOIMMUNITY; CELL DAMAGE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DISEASE ASSOCIATION; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENT DISEASE; SIGNAL TRANSDUCTION;

COMPLEMENT; IGG4; MEMBRANOUS NEPHROPATHY; PHOSPHOLIPASE A(2) RECEPTOR; PLA(2)R;

COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; KIDNEY GLOMERULUS; RECEPTORS, PHOSPHOLIPASE A2;

EID: 84886298109     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.08.004     Document Type: Article

References (108)

1. Jones D.B. Nephrotic glomerulonephritis. Am J Pathol 1957, 33:313-329.
2. Movat H.Z., McGreggor D.D. The fine structure of the glomerulus in membranous glomerulonephritis (lipoid nephrosis) in adults. Am J Clin Pathol 1959, 32:109-127.
3. Mellors R.C., Ortega L.G. Analytical pathology. III. New observations on the pathogenesis of glomerulonephritis, lipid nephrosis, periarteritis nodosa, and secondary amyloidosis in man. Am J Pathol 1956, 32:455-499.
4. McGrogan A., Franssen C.F., de Vries C.S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011, 26:414-430.
5. Menon S., Valentini R.P. Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol 2010, 25:1419-1428.
6. Kerlin B.A., Ayoob R., Smoyer W.E. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012, 7:513-520.
7. Dabade T.S., Grande J.P., Norby S.M., Fervenza F.C., Cosio F.G. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant 2008, 8:1318-1322.
8. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
9. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012, 2:139-274. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group.
10. Jennette J.C., Iskandar S.S., Dalldorf F.G. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983, 24:377-385.
11. Doi T., Mayumi M., Kanatsu K., Suehiro F., Hamashima Y. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol 1984, 58:57-62.
12. Huang C.C., Lehman A., Albawardi A., et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol 2013, 26:799-805.
13. Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 1994, 23:358-364.
14. Ohtani H., Wakui H., Komatsuda A., et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004, 19:574-579.
15. Larsen C.P., Messias N.C., Silva F.G., Messias E., Walker P.D. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013, 26:709-715.
16. Batsford S., Oite T., Takamiya H., Vogt A. Anionic binding sites in the glomerular basement membrane: possible role in the pathogenesis of immune complex glomerulonephritis. Ren Physiol 1980, 3:336-340.
17. Border W.A., Ward H.J., Kamil E.S., Cohen A.H. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest 1982, 69:451-461.
18. Adler S.G., Wang H., Ward H.J., Cohen A.H., Border W.A. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest 1983, 71:487-499.
19. Koyama A., Inage H., Kobayashi M., Narita M., Tojo S. Effect of chemical cationization of antigen on glomerular localization of immune complexes in active models of serum sickness nephritis in rabbits. Immunology 1986, 58:529-534.
20. Debiec H., Lefeu F., Kemper M.J., et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011, 364:2101-2110.
21. Schmiedeke T.M., Stöckl F.W., Weber R., Sugisaki Y., Batsford S.R., Vogt A. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 1989, 169:1879-1894.
22. Takekoshi Y., Tanaka M., Miyakawa Y., Yoshizawa H., Takahashi K., Mayumi M. Free "small" and IgG-associated "large" hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med 1979, 300:814-819.
23. Heymann W., Hackel D.B., Harwood S., Wilson S.G., Hunter J.L. Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 1959, 100:660-664.
24. Edgington T.S., Glassock R.J., Dixon F.J. Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science 1967, 155:1432-1434.
25. Feenstra K., van den Lee R., Greben H.A., Arends A., Hoedemaeker P.J. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. I. The natural history: a histologic and immunohistologic study at the light microscopic and the ultrastructural level. Lab Invest 1975, 32:235-242.
26. Couser W.G., Steinmuller D.R., Stilmant M.M., Salant D.J., Lowenstein L.M. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 1978, 62:1275-1287.
27. VanDamme B.J., Fleuren G.J., Bakker W.W., Vernier R.L., Hoedemaeker P.J. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 1978, 38:502-510.
28. Kerjaschki D., Farquhar M.G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982, 79:5557-5561.
29. Makker S.P., Singh A.K. Characterization of the antigen (gp600) of Heymann nephritis. Lab Invest 1984, 50:287-293.
30. Orlando R.A., Kerjaschki D., Kurihara H., Biemesderfer D., Farquhar M.G. gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci U S A 1992, 89:6698-6702.
31. Petermann A.T., Krofft R., Blonski M., et al. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003, 64:1222-1231.
32. Schulze M., Donadio J.V., Pruchno C.J., et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991, 40:533-538.
33. Salant D.J., Belok S., Madaio M.P., Couser W.G. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 1980, 66:1339-1350.
34. Perkinson D.T., Baker P.J., Couser W.G., Johnson R.J., Adler S. Membrane attack complex deposition in experimental glomerular injury. Am J Pathol 1985, 120:121-128.
35. Cybulsky A.V., Rennke H.G., Feintzeig I.D., Salant D.J. Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 1986, 77:1096-1107.
36. Baker P.J., Ochi R.F., Schulze M., Johnson R.J., Campbell C., Couser W.G. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 1989, 135:185-194.
37. Quigg R.J., Holers V.M., Morgan B.P., Sneed A.E. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol 1995, 154:3437-3443.
38. Schiller B., He C., Salant D.J., Lim A., Alexander J.J., Quigg R.J. Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. J Exp Med 1998, 188:1353-1358.
39. Rus H.G., Niculescu F.I., Shin M.L. Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 2001, 180:49-55.
40. Quigg R.J., Cybulsky A.V., Jacobs J.B., Salant D.J. Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells. Kidney Int 1988, 34:43-52.
41. Topham P.S., Haydar S.A., Kuphal R., Lightfoot J.D., Salant D.J. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 1999, 55:1763-1775.
42. Yuan H., Takeuchi E., Taylor G.A., McLaughlin M., Brown D., Salant D.J. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002, 13:946-956.
43. Saran A.M., Yuan H., Takeuchi E., McLaughlin M., Salant D.J. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003, 64:2072-2078.
44. Minto A.W., Kalluri R., Togawa M., Bergijk E.C., Killen P.D., Salant D.J. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy. Proc Assoc Am Physicians 1998, 110:207-217.
45. Floege J., Johnson R.J., Gordon K., et al. Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 1992, 42:573-585.
46. Lundgren S., Carling T., Hjälm G., et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997, 45:383-392.
47. Segawa Y., Hisano S., Matsushita M., et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol 2010, 25:1091-1099.
48. Endo M., Fuke Y., Tamano M., et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract 2004, 97:c147-53.
49. Zhang R., Zheng Z.Y., Lin J.S., Qu L.J., Zheng F. The continual presence of C3d but not IgG glomerular capillary deposition in stage I idiopathic membranous nephropathy in patients receiving corticosteroid treatment. Diagn Pathol 2012, 7:109.
50. Nangaku M., Shankland S.J., Couser W.G. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005, 16:1195-1204.
51. Collins A.B., Schneeberger E.E., Pascual M.A., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10:2208-2214.
52. Kusunoki Y., Itami N., Tochimaru H., Takekoshi Y., Nagasawa S., Yoshiki T. Glomerular deposition of C4 cleavage fragment (C4d) and C4-binding protein in idiopathic membranous glomerulonephritis. Nephron 1989, 51:17-19.
53. Val-Bernal J.F., Garijo M.F., Val D., Rodrigo E., Arias M. C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis. Histol Histopathol 2011, 26:1391-1397.
54. Espinosa-Hernandez M., Ortega-Salas R., Lopez-Andreu M., et al. C4d as a diagnostic tool in membranous nephropathy. Nefrologia 2012, 32:295-299.
55. Suzuki T., Horita S., Kadoya K., et al. C4d Immunohistochemistry in glomerulonephritis with different antibodies. Clin Exp Nephrol 2007, 11:287-291.
56. Song Y.S., Min K.W., Kim J.H., Kim G.H., Park M.H. Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis. Clin J Am Soc Nephrol 2012, 7:1947-1955.
57. Lhotta K., Wurzner R., Rumpelt H.J., Eder P., Mayer G. Membranous nephropathy in a patient with hereditary complete complement C4 deficiency. Nephrol Dial Transplant 2004, 19:990-993.
58. Iwaki D., Kanno K., Takahashi M., Endo Y., Matsushita M., Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011, 187:3751-3758.
59. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001, 167:2861-2868.
60. Roos A., Rastaldi M.P., Calvaresi N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006, 17:1724-1734.
61. Endo M., Ohi H., Ohsawa I., Fujita T., Matsushita M. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998, 13:1984-1990.
62. Lhotta K., Wurzner R., Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 1999, 14:881-886.
63. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995, 1:237-243.
64. Salant D.J. Genetic variants in membranous nephropathy: perhaps a perfect storm rather than a straightforward conformeropathy?. J Am Soc Nephrol 2013, 24:525-528.
65. Pucić M., Knezević A., Vidic J., et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 2011, 10:M111:010090.
66. Jennette J.C., Hipp C.G. Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens. Am J Clin Pathol 1985, 83:415-420.
67. Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J Immunol 2006, 176:1305-1310.
68. Lachmann P.J. The amplification loop of the complement pathways. Adv Immunol 2009, 104:115-149.
69. van der Neut Kolfschoten M., Schuurman J., Losen M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
70. Kawa S., Kitahara K., Hamano H., et al. A novel immunoglobulin-immunoglobulin interaction in autoimmunity. PLoS One 2008, 3:e1637.
71. Rispens T., Ooievaar-De Heer P., Vermeulen E., Schuurman J., van der Neut Kolfschoten M., Aalberse R.C. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol 2009, 182:4275-4281.
72. Makker S.P., Tramontano A. Idiopathic membranous nephropathy: an autoimmune disease. Semin Nephrol 2011, 31:333-340.
73. Debiec H., Guigonis V., Mougenot B., et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002, 346:2053-2060.
74. Debiec H., Nauta J., Coulet F., et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004, 364:1252-1259.
75. Ronco P. Secondary membranous nephropathy and other target antigens. Presented at: American Society of Nephrology Kidney Week; 2012 Nov 2; Philadelphia, PA.
76. Hoxha E., Harendza S., Zahner G., et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011, 26:2526-2532.
77. Qin W., Beck L.H., Zeng C., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011, 22:1137-1143.
78. Debiec H., Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011, 364:689-690.
79. Hofstra J.M., Wetzels J.F. Anti-PLA(2)R antibodies in membranous nephropathy: ready for routine clinical practice?. Neth J Med 2012, 70:109-113.
80. Hofstra J.M., Debiec H., Short C.D., et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012, 23:1735-1743.
81. Hoxha E., Kneißler U., Stege G., et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012, 82:797-804.
82. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22:1543-1550.
83. Beck L.H., Salant D.J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int 2010, 77:765-770.
84. Debiec H., Martin L., Jouanneau C., et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant 2011, 11:2144-2152.
85. Ayalon R., Beck L.H., Fervenza F.C., Cosio F.G., Brennan D.C., Salant D.J. Do anti-phospholipase A2 receptor antibodies predict recurrence of membranous nephropathy after transplantation?. J Am Soc Nephrol 2012, 23:64A.
86. Ma H., Beck L.H., Salant D.J. Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin complement pathway [abstract]. J Am Soc Nephrol 2011, 22:62A.
87. Qu Z., Liu G., Li J., et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012, 27:1931-1937.
88. Dähnrich C., Komorowski L., Probst C., et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013, 421C:213-218.
89. Debiec H., Hanoy M., Francois A., et al. Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol 2012, 23:1949-1954.
90. Bruschi M., Carnevali M.L., Murtas C., et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 2011, 74:2008-2017.
91. Murtas C., Bruschi M., Candiano G., et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012, 7:1394-1400.
92. Prunotto M., Carnevali M.L., Candiano G., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010, 21:507-519.
93. Rodriguez E.F., Cosio F.G., Nasr S.H., et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am J Transplant 2012, 12:1029-1038.
94. Blosser C.D., Ayalon R., Nair R., Thomas C., Beck L.H. Very early recurrence of anti-phospholipase A2 receptor-positive membranous nephropathy after transplantation. Am J Transplant 2012, 12:1637-1642.
95. Sekine H., Watanabe H., Gilkeson G.S. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol 2004, 172:3913-3921.
96. Kotzin B.L. Systemic lupus erythematosus. Cell 1996, 85:303-306.
97. Yamashina M., Takami T., Kanemura T., Orii T., Ojima A. Immunohistochemical demonstration of complement components in formalin-fixed and paraffin-embedded renal tissues. Lab Invest 1989, 60:311-316.
98. Chowdhury A.R., Ehara T., Higuchi M., Hora K., Shigematsu H. Immunohistochemical detection of immunoglobulins and complements in formaldehyde-fixed and paraffin-embedded renal biopsy tissues; an adjunct for diagnosis of glomerulonephritis. Nephrology (Carlton) 2005, 10:298-304.
99. Cunningham P.N., Quigg R.J. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005, 16:1214-1222.
100. Holers V.M., Rohrer B., Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol 2013, 735:137-154.
101. Cybulsky A.V., Quigg R.J., Salant D.J. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol 2005, 289:F660-F671.
102. Hofstra J.M., Beck L.H., Beck D.M., Wetzels J.F., Salant D.J. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011, 6:1286-1291.
103. Gunnarsson I., Schlumberger W., Rönnelid J. Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis. Am J Kidney Dis 2012, 59:585-586.
104. Svobodova B., Honsova E., Ronco P., Tesar V., Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 2013, 28:1839-1844.
105. Kanigicherla D., Gummadova J., McKenzie E.A., et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013, 83:940-948.
106. Coenen M.J., Hofstra J.M., Debiec H., et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 2013, 24:677-683.
107. Behnert A., Fritzler M.J., Teng B., et al. An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor. PLoS One 2013, 8:e61669.
108. Oh Y.J., Yang S.H., Kim D.K., Kang S.W., Kim Y.S. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One 2013, 8:e62151.